News

The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR

The mapping method revealed prominent microscopic abnormalities consistent with DR

Under the new policy, grant-making entities will be encouraged to fund post-market research investigating pharmacodynamics and pharmacokinetics for generic drugs that did not adequately enroll women, and sexual and gender minority populations in their clinical trials.

Investigators say the discovery highlights the importance of genetic consultation

The mapping method revealed prominent microscopic abnormalities consistent with DR

The trial is designed to enable a resubmission of a New Drug Application to the US FDA for reproxalap after receiving a Complete Response Letter last year.

Over 380 organizations representing patients, health care providers, the medical technology and biopharmaceutical industry, health plans and others endorse the legislation

Paying attention to high-resolution OCT is more important than ever

The NP-1/NP-1C preloaded IOL injector has already been made available in parts of Asia

Two randomized, double-masked, placebo-controlled, Phase 3 trials named REVEAL-1 and REVEAL-2 are expected to start in August 2024.

Metabolomics reflects the physiological state of a tissue and provides information about interactions between genetics, environment and lifestyle

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers from the Case Western Reserve University School of Medicine and the Cole Eye Institute have found that supplement melatonin could be linked to a decreased risk of age-related macular degeneration.

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

Simply slowing disease progression is no longer enough

All R&D for the drug will stop after the Phase 2a clinical trial failed to meet its primary endpoint of lowering IOP in patients with primary open-angle glaucoma.

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than the standard bimonthly aflibercept control group at all 6 time points through Week 24.

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

ARVO attendees took a deep dive into trends and explored the near future of vision science

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

The trial aims to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED)

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.

Investigators put forth a list of considerations for surgeons ahead of lens removal in pediatric patients

According to a study, the research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD